TransMedics Group (TMDX) Faces Securities Fraud Investigation Leading to Stock Decline
Market Chameleon (Mon, 3-Feb 3:34 AM ET)
Globe Newswire (Sun, 2-Feb 7:13 AM ET)
Globe Newswire (Sat, 1-Feb 5:05 PM ET)
PRNewswire (Fri, 31-Jan 8:14 PM ET)
TransMedics Group (TMDX) Plunges Amidst Allegations of Fraud, Organ Trafficking Hagens Berman
Globe Newswire (Fri, 31-Jan 12:26 PM ET)
Globe Newswire (Fri, 31-Jan 7:36 AM ET)
Globe Newswire (Wed, 29-Jan 8:11 AM ET)
Globe Newswire (Tue, 28-Jan 9:00 PM ET)
PRNewswire (Tue, 28-Jan 1:30 PM ET)
PRNewswire (Tue, 28-Jan 3:35 AM ET)
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Transmedics Group trades on the NASDAQ stock market under the symbol TMDX.
As of February 3, 2025, TMDX stock price climbed to $68.23 with 809,107 million shares trading.
TMDX has a beta of 1.20, meaning it tends to be more sensitive to market movements. TMDX has a correlation of 0.04 to the broad based SPY ETF.
TMDX has a market cap of $2.29 billion. This is considered a Mid Cap stock.
Last quarter Transmedics Group reported $109 million in Revenue and $.12 earnings per share. This fell short of revenue expectation by $-6 million and missed earnings estimates by -$.18.
In the last 3 years, TMDX traded as high as $177.37 and as low as $10.00.
The top ETF exchange traded funds that TMDX belongs to (by Net Assets): IJR, VTI, IWM, VB, VXF.
TMDX has underperformed the market in the last year with a return of -20.5%, while the SPY ETF gained +25.6%. In the last 3 month period, TMDX fell short of the market, returning -16.8%, while SPY returned +5.8%. However, in the most recent 2 weeks TMDX has outperformed the stock market by returning +19.3%, while SPY returned +0.3%.
TMDX support price is $63.70 and resistance is $71.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TMDX shares will trade within this expected range on the day.